P-glycoprotein

Type: Keyphrase

Name: P-glycoprotein

First reported May 09 2013 - Updated May 09 2013 - 1 reports

The Brain Entry of HIV-1 Protease Inhibitors Is Facilitated When Used in Combination

One hypothesis for persisting HIV-associated neurocognitive disorders (HAND) in effectively treated individuals is the limited permeation of antiretroviral agents (ARV) across the blood–brain barrier (BBB). However, the physicochemical factors limiting ... [Published Molecular Pharmaceutics - May 09 2013]

Entities: lipophilic, Protease, Drugs

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Dose-Dependent Targeted Suppression of P-glycoprotein Expression and Function in Caco-2 Cells

The efflux transporter P-glycoprotein (Pgp), encoded by the ABCB1 gene, decreases the bioavailability of a wide range of orally administered drugs. Drug permeability studies using the in vitro Caco-2 cell model commonly rely on small molecule modulators ... [Published Bionity.com - May 09 2013]

Entities: P-glycoprotein, dose-dependent, Suppression

First reported May 03 2013 - Updated May 03 2013 - 1 reports

University of North Carolina

Investigators at University of North Carolina Have Reported New Data on Bioorganic and Medicinal Chemistry

(NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Current study results on Bioorganic and Medicinal Chemistry have been published. According to news reporting originating from Chapel Hill, North Carolina, by NewsRx correspondents, research ... [Published NewsRX - May 03 2013]

Entities: Medicinal Chemistry, University of North Carolina, P-glycoprotein

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Dose-Dependent Targeted Suppression of P-glycoprotein Expression and Function in Caco-2 Cells

Entities: dose-dependent, P-glycoprotein, sirna, Suppression

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Blood–Brain Barrier

Efflux transporters located at the blood–brain barrier, such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), regulate the passage of many drugs in and out of the brain. Changes in the function and density of these proteins, in particular ... [Published Molecular Pharmaceutics - May 02 2013]

Entities: Positron Emission Tomography, Density, P-glycoprotein

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Potential Risk of Mulberry–Drug Interaction: Modulation on P-Glycoprotein and Cytochrome P450 3A

Mulberry is a fruit containing polyphenol antioxidants. Cyclosporine (CSP), a potent immunosuppressant with a narrow therapeutic range, is widely used in transplant patients. This study investigated the effect of co-administration of mulberry on the bioavailability ... [Published Journal of Agricultural and Food Chemistry - Apr 30 2013]

Entities: Morus (plant), P-glycoprotein, cyclosporine, Drugs

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Intestinal Absorption Mechanism of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems

Mirabegron, a weak-basic compound, is a potent and selective β3-adrenoceptor agonist for the treatment of overactive bladder. Mirabegron extended release formulation shows dose-dependent oral bioavailability in humans, which is likely attributable to ... [Published Molecular Pharmaceutics - Apr 24 2013]

Entities: Membrane, Absorption, P-glycoprotein

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Findings on Breast Cancer Detailed by Investigators at University of Minnesota

(NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Breast Cancer have been presented. According to news reporting originating in Minneapolis, Minnesota, by NewsRx journalists, research stated, "The study objective ... [Published NewsRX - Apr 19 2013]

Entities: University of Minnesota, Breast Cancer, P-glycoprotein, Central Nervous System

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Research from Lilly Research Laboratories Yields New Finding. . .

Research from Lilly Research Laboratories Yields New Findings on Molecular PharmaceuticsMolecular PharmaceuticsNewsRx.comBy a News Reporter-Staff News Editor at Drug Week -- Fresh data on Molecular Pharmaceutics are presented in a new report. According ... [Published Equities.com - Apr 17 2013]

Entities: Pharmaceutics, Eli Lilly & Company, Substrate

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells

by Chiara Riganti, Barbara Castella, Joanna Kopecka, Ivana Campia, Marta Coscia, Gianpiero Pescarmona, Amalia Bosia, Dario Ghigo, Massimo MassaiaDurable tumor cell eradication by chemotherapy is challenged by the development of multidrug-resistance (MDR) ... [Published Elites TV - Apr 15 2013]

Entities: Zoledronic Acid, ImmunoGen Inc, chemosensitivity, doxorubicin

First reported Apr 14 2013 - Updated Apr 14 2013 - 1 reports

Breast Cancer-Derived Microparticles Display Tissue Selectivity in the Transfer of Resistance Proteins to Cells

by Ritu Jaiswal, Frederick Luk, Penelope V. Dalla, Georges Emile Raymond Grau, Mary BebawyMicroparticles (MPs) play a vital role in cell communication by facilitating the horizontal transfer of cargo between cells. Recently, we described a novel "non-genetic" ... [Published Elites TV - Apr 14 2013]

Entities: Microparticles, Proteins, malignant, Transfers

Quotes

"Zenith Technology has a very strong reputation as a Clinical Contract Research Organization. Their capabilities will be extremely helpful in advancing our global development programs for Oraxol and Oratecan. I look forward to working closely with the Zenith team in conjunction with Hanmi Pharmaceuticals as we progress in our global development programs" said Rudolf Kwan, Chief Medical Officer of Kinex

Kinex and Zenith execute collaborative licensing agreement for cancer drugs [Published Zecco - May 17 2013]

"robust health care infrastructure will be needed.....infrastructure in the current U S health care system is woefully inadequate....Successful treatment of HCV infection has undeniable long-term benefits with respect to reducing morbidity and mortality......most challenging issue is not whether there will be medical tools to effectively manage and treat HCV infection, but whether the economic resources and societal commitment will be adequate to embark on an ambitious agenda to eliminate this global public healthhealth problem."

Current and Future Therapies for Hepatitis C Virus Infection, from NIH [Published National AIDS Treatment Advocacy Project - May 17 2013]

...According to news reporting out of Hannover, Germany, by NewsRx editors, research stated, "Epidemiological studies show that a positive correlation exists between the consumption of strongly heated meat and fish and the development of colorectal tumours. In this context, it has been postulated that the uptake of toxic substances formed during meat and fish processing such as heterocyclic aromatic amines (HCAs) may be causally related to colon carcinogenesis."

Researchers from University of Veterinary Medicine Report Ne. . . [Published Equities.com - May 08 2013]

...According to news reporting originating from Chapel Hill, North Carolina, by NewsRx correspondents, research stated, "In this study, 19 dicamphanoyl-dihydropyranochromone (DCP) and dicamphanoyl-dihydropyranoxanthone (DCX) derivatives, previously discovered as novel anti-HIV agents, were evaluated for their potential to reverse multi-drug resistance (MDR) in a cancer cell line over-expressing P-glycoprotein (P-gp)."

Investigators at University of North Carolina Have Reported New Data on Bioorganic and Medicinal ... [Published NewsRX - May 03 2013]

More Content

sort by: Date \| Relevance
Kinex and Zenith execute collaborative licensin... [Published Zecco - May 17 2013]
Current and Future Therapies for Hepatitis C Vi... [Published National AIDS Treatment Advocacy Project - May 17 2013]
Talon Therapeutics, Inc. Reports First Quarter ... [Published Nasdaq - May 15 2013]
PolyU Wins Top Prizes in Geneva’s Invention Expo [Published PRWeb - May 09 2013]
PolyU wins top prizes in Geneva’s Invention Expo [Published Prlog - May 09 2013]
The Brain Entry of HIV-1 Protease Inhibitors I... [Published Molecular Pharmaceutics - May 09 2013]
Dose-Dependent Targeted Suppression of P-glycop... [Published Bionity.com - May 09 2013]
Researchers from University of Veterinary Medic... [Published Equities.com - May 08 2013]
Kinex Pharmaceuticals and Zenith Technology Cor... [Published NewsBlaze - May 06 2013]
Investigators at University of North Carolina H... [Published NewsRX - May 03 2013]
Dose-Dependent Targeted Suppression of P-glycop... [Published Molecular Pharmaceutics - May 03 2013]
Factors That Limit Positron Emission Tomography... [Published Molecular Pharmaceutics - May 02 2013]
Intestinal Absorption Mechanism of Mirabegron, ... [Published Bionity.com - May 01 2013]
No Clinically Significant Interactions Between ... [Published National AIDS Treatment Advocacy Project - Apr 30 2013]
Potential Risk of Mulberry–Drug Interaction: Mo... [Published Journal of Agricultural and Food Chemistry - Apr 30 2013]
Intestinal Absorption Mechanism of Mirabegron, ... [Published Molecular Pharmaceutics - Apr 24 2013]
Antifungal Therapy for Invasive Aspergillosis [Published U.S.Pharmacist - Apr 19 2013]
Findings on Breast Cancer Detailed by Investiga... [Published NewsRX - Apr 19 2013]
Coagulation Abnormalities in Osteonecrosis and ... [Published Orthopedics Today - Apr 19 2013]
Research from Lilly Research Laboratories Yield... [Published Equities.com - Apr 17 2013]
Zoledronic Acid Restores Doxorubicin Chemosensi... [Published Elites TV - Apr 15 2013]
Breast Cancer-Derived Microparticles Display Ti... [Published Elites TV - Apr 14 2013]
Cyclic-AMP Mediated Regulation of ABCB mRNA Exp... [Published Elites TV - Apr 13 2013]
Talon Therapeutics, Inc. Reports Fourth Quarter... [Published Stockwatch - Apr 01 2013]
Pfizer’s BOSULIF® (bosutinib) Receives Conditio... [Published Stockwatch - Mar 28 2013]
In vivo gene sensors [Published PharmCast - Dec 28 2012]
Talon Therapeutics, Inc. Reports Third Quarter ... [Published GlobeNewswire - Nov 14 2012]
Compositions and methods relating to prevention... [Published PharmCast - Sep 19 2012]
NIH scientists develops new strategy for treati... [Published PharmaBiz - Sep 11 2012]
US FDA approves Talon Therapeutics' Marqibo [Published PharmaBiz - Aug 11 2012]